NYSE:SNN - Smith & Nephew Stock Price, Forecast & News

Smith & Nephew trades on the New York Stock Exchange (NYSE) under the ticker symbol "SNN."

Smith & Nephew announced a semi-annual dividend on Monday, February 24th. Shareholders of record on Friday, April 3rd will be paid a dividend of $0.462 per share on Wednesday, May 6th. This represents a yield of 1.4%. The ex-dividend date of this dividend is Thursday, April 2nd. View Smith & Nephew's Dividend History.

Smith & Nephew plc (NYSE:SNN) released its quarterly earnings results on Monday, November, 17th. The medical equipment provider reported $0.98 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.39 by $0.59. View Smith & Nephew's Earnings History.

Smith & Nephew is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Smith & Nephew.

Smith & Nephew updated its FY 2020 IntraDay earnings guidance on Thursday, February, 20th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $5.344-5.395 billion.

5 equities research analysts have issued 1-year price objectives for Smith & Nephew's shares. Their forecasts range from $6.00 to $52.00. On average, they anticipate Smith & Nephew's stock price to reach $29.00 in the next year. This suggests that the stock has a possible downside of 39.0%. View Analyst Price Targets for Smith & Nephew.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Smith & Nephew in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Smith & Nephew.

Media headlines about SNN stock have been trending somewhat positive recently, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Smith & Nephew earned a news sentiment score of 1.1 on InfoTrie's scale. They also gave media stories about the medical equipment provider a news buzz of 3.0 out of 10, indicating that recent media coverage is unlikely to have an impact on the stock's share price in the near future. View News Stories for Smith & Nephew.

Smith & Nephew saw a decline in short interest in the month of January. As of January 31st, there was short interest totalling 1,750,000 shares, a decline of 7.9% from the January 15th total of 1,900,000 shares. Based on an average daily volume of 592,200 shares, the days-to-cover ratio is currently 3.0 days. Approximately 0.4% of the company's shares are short sold. View Smith & Nephew's Current Options Chain.

Some companies that are related to Smith & Nephew include Intuitive Surgical (ISRG), Edwards Lifesciences (EW), Zimmer Biomet (ZBH), COLOPLAST A/S/ADR (CLPBY), Align Technology (ALGN), Steris (STE), DEMANT A S/ADR (WILYY), MSA Safety (MSA), Wound Management Technologies (WNDM), Wright Medical Group (WMGI), Avanos Medical (AVNS), Inogen (INGN), Establishment Labs (ESTA), RTI Surgical (RTIX) and Invacare (IVC).

Based on aggregate information from My MarketBeat watchlists, some companies that other Smith & Nephew investors own include Smith & Nephew (SN), Gilead Sciences (GILD), AbbVie (ABBV), RPM International (RPM), Alibaba Group (BABA), Pfizer (PFE), Alexion Pharmaceuticals (ALXN), Vertex Pharmaceuticals (VRTX), Bristol-Myers Squibb (BMY) and CVS Health (CVS).

Smith & Nephew's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include WCM Investment Management LLC (0.96%), Nuance Investments LLC (0.76%), Cambiar Investors LLC (0.73%), FMR LLC (0.26%), Bank of America Corp DE (0.26%) and Envestnet Asset Management Inc. (0.15%).

SNN stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Cambiar Investors LLC, State Street Corp, Connor Clark & Lunn Investment Management Ltd., New York State Common Retirement Fund, Jane Street Group LLC, Barclays PLC and Goldman Sachs Group Inc..

SNN stock was bought by a variety of institutional investors in the last quarter, including Nuance Investments LLC, WCM Investment Management LLC, Envestnet Asset Management Inc., Natixis Advisors L.P., Citigroup Inc., Raymond James & Associates, M&T Bank Corp and Stifel Financial Corp.

Shares of SNN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of SNN stock can currently be purchased for approximately $47.54.

Smith & Nephew has a market capitalization of $20.79 billion and generates $5.14 billion in revenue each year. The medical equipment provider earns $600 million in net income (profit) each year or $2.02 on an earnings per share basis. Smith & Nephew employs 16,377 workers across the globe.View Additional Information About Smith & Nephew.

The official website for Smith & Nephew is http://www.smith-nephew.com/.

Smith & Nephew's mailing address is 15 ADAM STREET, LONDON X0, WC2N 6LA. The medical equipment provider can be reached via phone at 44-20-7401-7646 or via email at [email protected]